|[September 04, 2013]
Glancy Binkow & Goldberg LLP Announces Class Action Lawsuit Against NuVasive, Inc.
LOS ANGELES --(Business Wire)--
Binkow & Goldberg LLP, representing investors of NuVasive,
Inc. ("NuVasive" or the "Company") (NASDAQ:NUVA), announces that a
class action lawsuit has been filed in the United States District Court
for the Southern District of California on behalf of a class (the
"Class") comprising all purchasers of NuVasive securities between
October 22, 2008 and July 30, 2013, inclusive (the "Class Period").
A COPY OF THE COMPLAINT
IS AVAILABLE FROM THE COURT OR FROM GLANCY BINKOW & GOLDBERG LLP. PLEASE
CONTACT US TOLL-FREE AT (888) 773-9224, OR AT (212) 682-5340, OR BY
EMAIL TO SHAREHOLDERS@GLANCYLAW.COM
TO DISCUSS THIS MATTER OR IF YOU PURCHASED NUVASIVE SHARES PRIOR TO THE
CLASS PERIOD. IF YOU INQUIRE BY EMAIL PLEASE INCLUDE YOUR MAILING
ADDRESS, TELEPHONE NUMBER AND NUMBER OF SHARES PURCHASED.
NuVasive is engaged in the design, development and marketing of
minimallydisruptive surgical products and procedurally integrated
solutions for the spine. The Complaint alleges that the Company issued
false and/or misleading statements and failed to disclose material
adverse facts about NuVasive's business, operations and prospects.
Specifically: (1) the Company improperly submitted false claims to
Medicare and Medicaid in violation of federal and state laws and
regulations; and (2) as a result of the foregoing, the Company's
statements were materially false and misleading at all relevant times.
On July 30, 2013, the Company disclosed that it had received a federal
administrative subpoena from the Office of the Inspector General of the
U.S. Department of Health and Human Services in connection with an
investigation into "possible false or otherwise improper claims
submitted to Medicare and Medicaid." As a result of this news, NuVasive
securities declined $3.28 per share, or over 12%, to close at $22.84 per
share on July 31, 2013.
If you are a member of the Class described above you may move the Court
no later than October 28, 2013 to serve as lead plaintiff; however, you
must meet certain legal
requirements. If you wish to learn
more about this action, or if you purchased NuVasive shares prior to
the Class Period and have any questions concerning this announcement or
your rights or interests with respect to these matters, please contact Michael
Goldberg, Esquire, of Glancy Binkow & Goldberg LLP, 1925 Century
Park East, Suite 2100, Los Angeles, California 90067, Toll Free at (888)
773-9224, or contact Gregory
Linkh, Esquire, of Glancy Binkow & Goldberg LLP at 122 E. 42nd
Street, Suite 2920, New York, New York 10168, at (212) 682-5340, by
e-mail to firstname.lastname@example.org,
or visit our website at http://www.glancylaw.com.
If you inquire by email please include your mailing address, telephone
number and number of shares purchased.
This press release may be considered Attorney Advertising in some
jurisdictions under the applicable law and ethical rules.
[ Back To Technology News's Homepage ]